Switch to:
Also traded in: Austria, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISRG's Cash-to-Debt is ranked higher than
98% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISRG' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.35  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.88
ISRG's Equity-to-Asset is ranked higher than
88% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ISRG: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
ISRG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 0.9
Current: 0.88
0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
97% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 40.65
Beneish M-Score: -2.70
WACC vs ROIC
7.52%
29.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 33.14
ISRG's Operating Margin % is ranked higher than
97% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ISRG: 33.14 )
Ranked among companies with meaningful Operating Margin % only.
ISRG' s Operating Margin % Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 33.14
25.56
40.3
Net Margin % 30.16
ISRG's Net Margin % is ranked higher than
96% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ISRG: 30.16 )
Ranked among companies with meaningful Net Margin % only.
ISRG' s Net Margin % Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.16
Current: 30.16
19.65
30.16
ROE % 18.11
ISRG's ROE % is ranked higher than
87% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ISRG: 18.11 )
Ranked among companies with meaningful ROE % only.
ISRG' s ROE % Range Over the Past 10 Years
Min: 12.17  Med: 18.96 Max: 21.36
Current: 18.11
12.17
21.36
ROA % 15.91
ISRG's ROA % is ranked higher than
92% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. ISRG: 15.91 )
Ranked among companies with meaningful ROA % only.
ISRG' s ROA % Range Over the Past 10 Years
Min: 10.59  Med: 16.51 Max: 18.44
Current: 15.91
10.59
18.44
ROC (Joel Greenblatt) % 149.15
ISRG's ROC (Joel Greenblatt) % is ranked higher than
98% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. ISRG: 149.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISRG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 149.15
117.99
245.9
3-Year Revenue Growth Rate 6.80
ISRG's 3-Year Revenue Growth Rate is ranked higher than
57% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ISRG: 6.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISRG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.65 Max: 57.1
Current: 6.8
0
57.1
3-Year EBITDA Growth Rate 4.80
ISRG's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ISRG: 4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISRG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: 29.4 Max: 318.7
Current: 4.8
-62.8
318.7
3-Year EPS without NRI Growth Rate 3.80
ISRG's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ISRG: 3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISRG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.5  Med: 20.9 Max: 76.8
Current: 3.8
-61.5
76.8
GuruFocus has detected 5 Warning Signs with Intuitive Surgical Inc ISRG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISRG's 30-Y Financials

Financials (Next Earnings Date: 2018-01-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ISRG Guru Trades in Q4 2016

Ron Baron 11,216 sh (New)
Joel Greenblatt 2,698 sh (New)
John Paulson 10,100 sh (New)
John Hussman 10,000 sh (New)
Paul Tudor Jones 1,208 sh (New)
Steven Cohen 12,200 sh (+212.82%)
Jim Simons 199,891 sh (+142.97%)
Robert Olstein 12,300 sh (+75.71%)
Pioneer Investments 5,081 sh (+37.03%)
Lee Ainslie 1,750 sh (unchged)
Steven Cohen 20,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 56,174 sh (unchged)
Manning & Napier Advisors, Inc 159,680 sh (-3.35%)
Jeremy Grantham 53,233 sh (-23.03%)
Vanguard Health Care Fund 186,869 sh (-23.15%)
Ray Dalio 1,700 sh (-77.03%)
» More
Q1 2017

ISRG Guru Trades in Q1 2017

George Soros 400 sh (New)
Paul Tudor Jones 15,664 sh (+1196.69%)
Steven Cohen 34,600 sh (+183.61%)
Vanguard Health Care Fund 186,869 sh (unchged)
Joel Greenblatt Sold Out
John Hussman Sold Out
Lee Ainslie Sold Out
Pioneer Investments Sold Out
Ray Dalio Sold Out
Jim Simons 194,970 sh (-2.46%)
Ron Baron 10,923 sh (-2.61%)
John Paulson 7,400 sh (-26.73%)
Robert Olstein 8,600 sh (-30.08%)
Jeremy Grantham 31,736 sh (-40.38%)
Manning & Napier Advisors, Inc 51,049 sh (-68.03%)
Eaton Vance Worldwide Health Sciences Fund 46,205 sh (-17.75%)
» More
Q2 2017

ISRG Guru Trades in Q2 2017

Lee Ainslie 4,240 sh (New)
Jim Simons 307,100 sh (+57.51%)
John Paulson 10,200 sh (+37.84%)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Ron Baron 10,344 sh (-5.30%)
Vanguard Health Care Fund 161,369 sh (-13.65%)
Manning & Napier Advisors, Inc 40,653 sh (-20.36%)
Robert Olstein 4,200 sh (-51.16%)
Eaton Vance Worldwide Health Sciences Fund 39,163 sh (-15.24%)
» More
Q3 2017

ISRG Guru Trades in Q3 2017

Paul Tudor Jones 2,025 sh (New)
Steven Cohen 23,200 sh (New)
Jim Simons 428,600 sh (+39.56%)
Lee Ainslie 5,501 sh (+29.74%)
John Paulson Sold Out
Ron Baron 9,682 sh (-6.40%)
Manning & Napier Advisors, Inc 36,845 sh (-9.37%)
Robert Olstein 3,400 sh (-19.05%)
Vanguard Health Care Fund 92,705 sh (-42.55%)
Eaton Vance Worldwide Health Sciences Fund 30,965 sh (-20.93%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -42.55%0.14%$307.22 - $348.79 $ 398.1522%278,115
Ron Baron 2017-09-30 Reduce -6.40%$307.22 - $348.79 $ 398.1522%29,046
Robert Olstein 2017-09-30 Reduce -19.05%0.1%$307.22 - $348.79 $ 398.1522%10,200
John Paulson 2017-09-30 Sold Out 0.13%$307.22 - $348.79 $ 398.1522%0
Vanguard Health Care Fund 2017-06-30 Reduce -13.65%0.04%$253.11 - $318.05 $ 398.1538%484,107
Ron Baron 2017-06-30 Reduce -5.30%$253.11 - $318.05 $ 398.1538%31,032
John Paulson 2017-06-30 Add 37.84%0.04%$253.11 - $318.05 $ 398.1538%30,600
Robert Olstein 2017-06-30 Reduce -51.16%0.43%$253.11 - $318.05 $ 398.1538%12,600
George Soros 2017-06-30 Sold Out 0.01%$253.11 - $318.05 $ 398.1538%0
Ron Baron 2017-03-31 Reduce -2.61%$209.83 - $255.77 $ 398.1568%32,769
Robert Olstein 2017-03-31 Reduce -30.08%0.3%$209.83 - $255.77 $ 398.1568%25,800
John Paulson 2017-03-31 Reduce -26.73%0.02%$209.83 - $255.77 $ 398.1568%22,200
George Soros 2017-03-31 New Buy0.01%$209.83 - $255.77 $ 398.1568%1,200
Joel Greenblatt 2017-03-31 Sold Out 0.02%$209.83 - $255.77 $ 398.1568%0
Vanguard Health Care Fund 2016-12-31 Reduce -23.15%0.09%$206.34 - $241.54 $ 398.1581%560,607
Robert Olstein 2016-12-31 Add 75.71%0.44%$206.34 - $241.54 $ 398.1581%36,900
Ron Baron 2016-12-31 New Buy0.04%$206.34 - $241.54 $ 398.1581%33,648
John Paulson 2016-12-31 New Buy0.08%$206.34 - $241.54 $ 398.1581%30,300
Joel Greenblatt 2016-12-31 New Buy0.02%$206.34 - $241.54 $ 398.1581%8,094
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:BSX, NYSE:ZBH, NYSE:SYK, NYSE:EW, NAS:ALGN, LSE:SN., XSWX:SOON, NYSE:TFX, NYSE:VAR, NAS:ABMD, ASX:COH, OCSE:WDH, XPAR:DIM, SZSE:300003, NZSE:FPH, LSE:CTEC, NAS:MASI, OCSE:GN, OSTO:EKTA B, OCSE:AMBU B » details
Traded in other countries:ISRG.Austria, IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Headquarter Location:USA
Intuitive Surgical Inc designs, manufactures, markets da Vinci Surgical Systems, and related instruments. The da Vinci surgery, combines the benefits of minimally invasive surgery for patients with the ease of use, precision and dexterity of open surgery.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. Intuitive Surgical also provides the instrumentation, disposable accessories, and warranty services for the system. The firm has placed roughly 4,000 da Vinci systems in hospitals worldwide, with 2,600 installations in the U.S. and a growing number in emerging markets.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Vanguard Health Care Fund Trims Positions in Vertex, Regeneron, Illumina Fund's largest 3rd-quarter sales
Founded in 1984, the Vanguard Health Care Fund (Trades, Portfolio) is managed by Jean Hynes. During the third quarter, the fund reduced its positions in the following stocks: Read more...
New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform
Largest Insider Trades of the Week Radius Health, Del Taco Restaurants among stocks bought by insiders
The GuruFocus All-In-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “October 2017” and All Insider Sales to “$5,000,000+." Read more...
Intuitive Surgical Reports New Employee Option Grants for August 2017
Intuitive Surgical Board of Directors Approves a Three-for-One Stock Split
Intuitive Surgical Reports New Employee Option Grants for July 2017
Intuitive Surgical Reports New Employee Option Grants for June 2017
5 Companies Reach Yearly Highs Corning, Salesforce among those achieving milestones
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
Intuitive Surgical Receives FDA Clearance for Latest da Vinci® Robotic-Assisted Surgical System
Intuitive Surgical Reports New Employee Option Grants for May 2017

Ratios

vs
industry
vs
history
PE Ratio 51.38
ISRG's PE Ratio is ranked lower than
73% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. ISRG: 51.38 )
Ranked among companies with meaningful PE Ratio only.
ISRG' s PE Ratio Range Over the Past 10 Years
Min: 17.76  Med: 37.7 Max: 107.13
Current: 51.38
17.76
107.13
Forward PE Ratio 41.84
ISRG's Forward PE Ratio is ranked lower than
67% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ISRG: 41.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 51.38
ISRG's PE Ratio without NRI is ranked lower than
74% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. ISRG: 51.38 )
Ranked among companies with meaningful PE Ratio without NRI only.
ISRG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.73  Med: 37.7 Max: 106.5
Current: 51.38
17.73
106.5
Price-to-Owner-Earnings 56.81
ISRG's Price-to-Owner-Earnings is ranked lower than
68% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. ISRG: 56.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ISRG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.18  Med: 40.68 Max: 110.25
Current: 56.81
18.18
110.25
PB Ratio 9.01
ISRG's PB Ratio is ranked lower than
86% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ISRG: 9.01 )
Ranked among companies with meaningful PB Ratio only.
ISRG' s PB Ratio Range Over the Past 10 Years
Min: 2.81  Med: 6 Max: 15.72
Current: 9.01
2.81
15.72
PS Ratio 15.52
ISRG's PS Ratio is ranked lower than
86% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ISRG: 15.52 )
Ranked among companies with meaningful PS Ratio only.
ISRG' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 9.76 Max: 24.3
Current: 15.52
4.15
24.3
Price-to-Free-Cash-Flow 50.57
ISRG's Price-to-Free-Cash-Flow is ranked lower than
69% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. ISRG: 50.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ISRG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.4  Med: 31.32 Max: 94.73
Current: 50.57
18.4
94.73
Price-to-Operating-Cash-Flow 42.34
ISRG's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. ISRG: 42.34 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ISRG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.33  Med: 27.23 Max: 84.58
Current: 42.34
11.33
84.58
EV-to-EBIT 42.81
ISRG's EV-to-EBIT is ranked lower than
72% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. ISRG: 42.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.5 Max: 74.4
Current: 42.81
10.2
74.4
EV-to-EBITDA 39.07
ISRG's EV-to-EBITDA is ranked lower than
80% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. ISRG: 39.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 24 Max: 61.9
Current: 39.07
9.4
61.9
EV-to-Revenue 14.21
ISRG's EV-to-Revenue is ranked lower than
83% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ISRG: 14.21 )
Ranked among companies with meaningful EV-to-Revenue only.
ISRG' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.6  Med: 9.1 Max: 24
Current: 14.21
3.6
24
PEG Ratio 13.13
ISRG's PEG Ratio is ranked lower than
91% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. ISRG: 13.13 )
Ranked among companies with meaningful PEG Ratio only.
ISRG' s PEG Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.03 Max: 18.01
Current: 13.13
0.13
18.01
Shiller PE Ratio 85.98
ISRG's Shiller PE Ratio is ranked lower than
75% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. ISRG: 85.98 )
Ranked among companies with meaningful Shiller PE Ratio only.
ISRG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.24  Med: 71.35 Max: 282.22
Current: 85.98
44.24
282.22
Current Ratio 4.76
ISRG's Current Ratio is ranked higher than
76% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ISRG: 4.76 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.63 Max: 7.43
Current: 4.76
2.07
7.43
Quick Ratio 4.39
ISRG's Quick Ratio is ranked higher than
79% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ISRG: 4.39 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.32 Max: 7.07
Current: 4.39
1.72
7.07
Days Inventory 82.14
ISRG's Days Inventory is ranked higher than
77% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. ISRG: 82.14 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 55.48  Med: 74.23 Max: 91.85
Current: 82.14
55.48
91.85
Days Sales Outstanding 57.07
ISRG's Days Sales Outstanding is ranked higher than
59% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. ISRG: 57.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.96 Max: 79.2
Current: 57.07
48.57
79.2
Days Payable 32.41
ISRG's Days Payable is ranked lower than
78% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ISRG: 32.41 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 32.39 Max: 58.29
Current: 32.41
23.81
58.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. ISRG: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -2.1 Max: 2.4
Current: -0.5
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 30.53
ISRG's Price-to-Net-Cash is ranked lower than
75% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.17 vs. ISRG: 30.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISRG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.88  Med: 21.55 Max: 278
Current: 30.53
2.88
278
Price-to-Net-Current-Asset-Value 19.89
ISRG's Price-to-Net-Current-Asset-Value is ranked lower than
80% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. ISRG: 19.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISRG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.21  Med: 12.34 Max: 28.53
Current: 19.89
2.21
28.53
Price-to-Tangible-Book 9.69
ISRG's Price-to-Tangible-Book is ranked lower than
76% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. ISRG: 9.69 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISRG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.05  Med: 6.03 Max: 16.47
Current: 9.69
2.05
16.47
Price-to-Intrinsic-Value-Projected-FCF 3.65
ISRG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
67% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ISRG: 3.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ISRG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.62 Max: 19.2
Current: 3.65
1.45
19.2
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.80
ISRG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
59% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. ISRG: 1.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ISRG' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.11  Med: 1.39 Max: 3.75
Current: 1.8
1.11
3.75
Price-to-Median-PS-Value 1.59
ISRG's Price-to-Median-PS-Value is ranked lower than
74% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ISRG: 1.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISRG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.96 Max: 2.15
Current: 1.59
0.32
2.15
Price-to-Graham-Number 4.70
ISRG's Price-to-Graham-Number is ranked lower than
75% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ISRG: 4.70 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ISRG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.8  Med: 3.53 Max: 8.01
Current: 4.7
1.8
8.01
Earnings Yield (Greenblatt) % 2.35
ISRG's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. ISRG: 2.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISRG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 3.8 Max: 9.8
Current: 2.35
1.3
9.8
Forward Rate of Return (Yacktman) % 6.39
ISRG's Forward Rate of Return (Yacktman) % is ranked lower than
54% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. ISRG: 6.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ISRG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 28.35 Max: 145.5
Current: 6.39
1
145.5

More Statistics

Revenue (TTM) (Mil) $2,993.40
EPS (TTM) $ 7.75
Beta0.86
Short Percentage of Float4.31%
52-Week Range $203.57 - 400.00
Shares Outstanding (Mil)112.05

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,082 3,521 3,889
EPS ($) 8.29 9.69 10.65
EPS without NRI ($) 8.29 9.69 10.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.63%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}